Day 1

Opening Session

Introduction of Roger Glass Lecture - Julie Bines

Third  Roger Glass Lecture: Can we do better? Oral vaccines in the developing world - Gagandeep Kang

Introduction of Australia Keynote - Roger Glass

Australia's role on the global vaccine stage - Sir Gustav Nossal

Session I: Global & Regional Experience with Vaccines

Global Perspective of rotavirus vaccines: Policy, supply volumes and pricing - Duncan Steele

Global Sentinel Site Surveillance Network - Adam Cohen

Rotavirus Vaccine Introduction: Experiences and Lessons Learned in Latin American Countries - Lucia de Oliveira

Rotavirus Vaccine introductions in  the WHO African Region: Progress, Experiences, challenges and way forward - Jason Mwenda

Session II: Post-Licensure Impact and Safety of Rotavirus Vaccination 

Long term impact of rotavirus vaccination in the United States - Daniel Payne

Long term impact of rotavirus vaccination in the Western Europe - Timo Vesikari

Highlights of data on rotavirus vaccine impact in a densely populated country in Africa : Rwanda - Jacqueline Tate

Highlights of data on rotavirus vaccine impact in a sparsely populated country in Africa : Botswana - David Goldfarb

Impact of Rotavirus Vaccination in the Eastern European countries of Armenia and Moldova - Margaret Cortese

Session III : Poster Session

Effectiveness of a China-made live attenuated rotavirus vaccine (LLR): results from a population-based case-control study - Xuan-Yi Wang

Rotavirus Vaccine Effectiveness in Hong Kong Young Children - Tony Nelson

Assessment of intussusception risk in Mexican infants under 9 months of age after administration of pentavalent rotavirus vaccine -Marcelino Esparza-Aguilar

Rotavirus vaccine impact on diarrhea associated child mortality, hospital admissions and clinical visits in Bolivia - Volga Iniguez Rojas

Session IV: Women Leaders in the Scientific Advancement of Rotavirus – Tribute to Ruth Bishop

Toyoko Nakagomi

Julie Bines

Miren Itturiza-Gomara

Michelle Groome

Irrene Perez Schael

Gagandeep Kang

Kathleen Neuzil 

Day 2

Session V: Challenges and Opportunities in Asia Pacific Region

Process & Introduction in India -  Pradeep Haldar

Bangladesh: How to move from data to implementation - K. Zaman & Tajul_Islam_Bari

Effectiveness of rotavirus vaccine effectiveness in Thailand in a pilot demonstration project - Suchada Jiamsiri

Philippines Experience - Elvira Dayrit

Country Spotlight: Fiji Fiona Russell

Session VI: New insights into rotavirus pathogenesis and immunity

New insights into pathogenesis and immunity - Sasirekha Ramani

Does the intestinal microbiome impact rotavirus immunogenicity - Vanessa Harris

Host Cell Invasion - Barbara Coulson

Rotavirus infection and genetic susceptibility: the role of Lewis/ABO group antigens - Lennart Svennson

IPV Switch Impact on Rotavirus Vaccine Response & Performance - Umesh Parashar

New insights into the generation of heterotypic immunity to rotaviruses - Harry Greenberg

Session VII: Ruth Bishop Lecture

Rotavirus (RV) Genotype Trends in the United States 2005-2014 - Jon Gentsch

Session VIII: Policy Session

Comprehensive approach to Prevention and Treatment of Diarrhea -  Mathuram Santosham

Perspectives on the history of vaccine and immunization policy development - Jon Andrus

Current general RV policy issues - Carsten Mantel

The Expanding Rotavirus Vaccine Landscape: Lessons learned from influenza vaccines - Kathleen Neuzil

Session IX: Poster Session II

Rotavirus genotypes identified in children with acute gastroenteritis in states administering RotaTeq compared to Rotarix: Results of the Australian Rotavirus Surveillance Program 2007-2015 - Susie Roczo-Farkas

Early B cell responses following rotavirus vaccination and infection in Indian children - Sudhir Babji

The complex evolutionary dynamics of global rotavirus G1, G2, G3, P[4] and P[8] genes - Celest Donato

Rotavirus remains the leading etiology of diarrhea despite rotavirus vaccination: results using quantitative molecular diagnostics in a clinical trial in Dhaka, Bangladesh (PROVIDE) and a vaccine effectiveness study in Haydom, Tanzania - James Platts-Mills

Day 3

Session X: Current and Future Rotavirus Vaccines

The Rotavirus Vaccine Pipeline and Priorities for Development - Carl Kirkwood

Perspectives from the Currently Available WHO prequalified Vaccines

Humanrotavirusvaccine: A decade of experience vaccinating infants worldwide - Bernd Benninghoff

RotaTeq- An update - Susan Kaplan

Indigenous rotavirus vaccine does not require buffering. The ROTAVAC™ experience - Krishna Mohan 

Phase 3 efficacy data of a new pentavalent bovine-human reassortant rotavirus vaccine in India - Prasad Kulkarni

Phase 3 efficacy data of a new pentavalent bovine-human reassortant rotavirus vaccine in Niger - Rebecca Grais

A novel licensing strategy. Immunogenicity comparison to a pre-qualified vaccine - Badri Patnaik

Immunogenicity and efficacy of the RV3-BB neonatal schedule in Indonesian infants - Cahya Dewi & Julie Bines

Recent advances in the development of an inactivated rotavirus vaccine: from enhanced manufacture to microneedle patch delivery - Baoming Jiang

Safety and immunogenicity of the P2 VP8  non-replicating rotavirus vaccine in South African infants - Michelle Groome

A thermostable rotavirus vaccine approach - Ajit Pal Singh

Session XI: Cost-Effectiveness & Financing

Cost-effectiveness and financing analyses and considerations in Asia - Clint Pecenka

Thailand’s perspective on cost-effectiveness and financing of vaccines - Sripen Tantivess

Key issues for RV vaccine policy in Gavi graduating countries - Melissa Ko

Country Spotlight: The human costs of rotavirus diarrhea in Malawi - Naor Bar-Zeev